Company profile
Wandercraft
Wandercraft develops self-balancing robotic exoskeletons for rehabilitation and personal mobility. Its Atalante X system supports gait therapy in clinical...
Facts
- Segment
- EXOSKELETON
- Country
- FR
- Headquarters
- Paris
- Founded
- 2012
- Categories
- Medical, Exoskeleton, Rehabilitation, Humanoids
- Focus
- Healthcare
- Flagship
- Calvin-40
- Website
- https://www.wandercraft.eu
About Wandercraft
Atalante X uses powered hip, knee and ankle joints with active balance control to support hands-free gait rehabilitation. Therapists can select walking patterns and assistance modes for patients with severe gait impairments, including people who cannot rely on crutches or upper-body support.
Eve applies the same self-balancing principle to personal mobility at home and in the community. Wandercraft is building a continuum from clinical rehabilitation with Atalante X to upright everyday movement with Eve, alongside distribution and regulatory programmes for consumer access.
Market context
DEPLOYMENT
Summary
Type: Exoskeleton builder
Core: Atalante X
Function: Gait rehabilitation
Audience: Clinics
Products
- Atalante X — clinical rehabilitation exoskeleton
- Calvin-40 — humanoid
Research, Articles and recent verified events
- Ecuador authorises Wandercraft Atalante X for clinical rehabilitation — 2026-07-27
- Renault Group deploys 350 Wandercraft Calvin-40 humanoid robots — 2026-03-12
- Atalante X powered exoskeleton highlighted in rehabilitation study — 2025-08-01
- Wandercraft secures €64.3 million in Series D funding — 2025-06-11
- Wandercraft's Atalante X receives second FDA clearance — 2024-02-13
- Wandercraft secures €25M EIB financing for exoskeleton development — 2023-12-28